Hormonal
Once-weekly semaglutide (1.0 mg) reduces ad libitum energy intake by approximately 24% through mechanisms of reduced appetite, improved control of eating, and lower preference for high-fat foods, leading to significant body weight loss without compensatory increases in energy expenditure.
Take once-weekly semaglutide (titrated to 1.0 mg over 12 weeks) to reduce hunger, improve control over eating, and lower preference for high-fat foods. This leads to a ~24% reduction in daily calorie intake and significant fat loss, without needing to increase exercise or metabolic rate. Expect mild GI side effects initially.
After 12 weeks of treatment, ad libitum energy intake was substantially lower with semaglutide vs placebo with a corresponding loss of body weight observed with semaglutide. In addition to reduced energy intake, likely mechanisms for semaglutide-induced weight loss included less appetite and food cravings, better control of eating and lower relative preference for fatty, energy-dense foods.
Why this rating
Randomized, double-blind, placebo-controlled crossover trial with 30 subjects; high internal validity but small sample size.
Source
Effects of once‐weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity
John E. Blundell et al. · Diabetes Obesity and Metabolism · 2017
DOI 10.1111/dom.12932
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →